Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Expression of CD21/CD35 on splenic B lymphocytes. BALB/c splenocytes were stained with PE-conjugated anti-mouse CD45R/B220 mAb RA3-6B2 (Cat. No. 553089/553090) and either purified rat IgG2b, κ isotype control mAb A95-1 (Cat. No. 553986, left panel) or purified mAb 7G6 (right panel), followed by FITC-conjugated anti-rat IgG2b mAb RG7/11.1 (Cat. No. 553900). Flow cytometry was performed on a BD FACScan™ flow cytometry system.
Expression of CD21/CD35 on splenic B lymphocytes. BALB/c splenocytes were stained with PE-conjugated anti-mouse CD45R/B220 mAb RA3-6B2 (Cat. No. 553089/553090) and either purified rat IgG2b, κ isotype control mAb A95-1 (Cat. No. 553986, left panel) or purified mAb 7G6 (right panel), followed by FITC-conjugated anti-rat IgG2b mAb RG7/11.1 (Cat. No. 553900). Flow cytometry was performed on a BD FACScan™ flow cytometry system.
Expression of CD21/CD35 on splenic B lymphocytes. BALB/c splenocytes were stained with PE-conjugated anti-mouse CD45R/B220 mAb RA3-6B2 (Cat. No. 553089/553090) and either purified rat IgG2b, κ isotype control mAb A95-1 (Cat. No. 553986, left panel) or purified mAb 7G6 (right panel), followed by FITC-conjugated anti-rat IgG2b mAb RG7/11.1 (Cat. No. 553900). Flow cytometry was performed on a BD FACScan™ flow cytometry system.
Expression of CD21/CD35 on splenic B lymphocytes. BALB/c splenocytes were stained with PE-conjugated anti-mouse CD45R/B220 mAb RA3-6B2 (Cat. No. 553089/553090) and either purified rat IgG2b, κ isotype control mAb A95-1 (Cat. No. 553986, left panel) or purified mAb 7G6 (right panel), followed by FITC-conjugated anti-rat IgG2b mAb RG7/11.1 (Cat. No. 553900). Flow cytometry was performed on a BD FACScan™ flow cytometry system.
Expression of CD21/CD35 on splenic B lymphocytes. BALB/c splenocytes were stained with PE-conjugated anti-mouse CD45R/B220 mAb RA3-6B2 (Cat. No. 553089/553090) and either purified rat IgG2b, κ isotype control mAb A95-1 (Cat. No. 553986, left panel) or purified mAb 7G6 (right panel), followed by FITC-conjugated anti-rat IgG2b mAb RG7/11.1 (Cat. No. 553900). Flow cytometry was performed on a BD FACScan™ flow cytometry system.
Expression of CD21/CD35 on splenic B lymphocytes. BALB/c splenocytes were stained with PE-conjugated anti-mouse CD45R/B220 mAb RA3-6B2 (Cat. No. 553089/553090) and either purified rat IgG2b, κ isotype control mAb A95-1 (Cat. No. 553986, left panel) or purified mAb 7G6 (right panel), followed by FITC-conjugated anti-rat IgG2b mAb RG7/11.1 (Cat. No. 553900). Flow cytometry was performed on a BD FACScan™ flow cytometry system.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
The 7G6 antibody recognizes an epitope shared by 145-150-kDa and 190-kDa complement receptor proteins, originally designated CR2 (CD21) and CR1 (CD35), respectively. In the mouse, CD21 and CD35 are expressed on the majority of peripheral B lymphocytes, on the majority of resident peritoneal macrophages and mast cells, on peripheral blood granulocytes after treatment with N-formyl-Met-Leu-Phe, and on follicular dendritic cells, but not on thymocytes, T cells, erythrocytes, or platelets. CD21 is a ligand-binding component of the CD19/CD21/CD81 signal-transduction complex associated with the antigen receptor on B lymphocytes. CD21/CD35 also co-localizes with CD19 on the surface of peritoneal mast cells. Cr2null mice display impaired inflammatory and humoral immune responses in vivo. The 7G6 mAb has been reported to inhibit rosette formation by C3d-bearing sheep erythrocytes, to block the complement dependent trapping of immune complexes by follicular dendritic cells, and to down-regulate mouse CD21/CD35 expression upon in vivo application, thus inhibiting primary antibody responses to immunization. Co-stimulation of B-cell differentiation via Sepharose-coupled 7G6 antibody has also been observed. The 7G6 mAb recognizes an epitope on CD35 distinct from the epitope recognized by anti-mouse CD35, clone 8C12, and it does not block binding of 8C12 mAb to mouse CD35.
This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.